bioAffinity Expands CyPath Lung Test to Monitor Lung Cancer Recurrence
Event summary
- bioAffinity Technologies is advancing its CyPath Lung test for surveillance of lung cancer survivors post-treatment.
- The test analyzes the lung microenvironment in real-time, providing a binary result to assess malignancy risk.
- CyPath Lung has demonstrated 92% sensitivity and 99% negative predictive value in detecting lung cancer in high-risk patients.
- The company aims to complement CT surveillance with actionable information for evaluating new or changing pulmonary nodules.
- CyPath Lung is marketed as a Laboratory Developed Test (LDT) under CLIA oversight.
The big picture
bioAffinity's expansion of CyPath Lung into post-treatment surveillance addresses a critical gap in lung cancer care, where recurrence rates range from 20% to 55%. This move aligns with broader industry trends towards personalized and non-invasive monitoring solutions, potentially improving patient outcomes and reducing healthcare costs. The company's ability to leverage its existing clinical data and commercial experience will be key to successfully navigating this new application.
What we're watching
- Clinical Validation
- Whether CyPath Lung's performance in early detection translates to post-treatment surveillance.
- Regulatory Compliance
- The impact of evolving regulations on Laboratory Developed Tests (LDTs) on bioAffinity's operations.
- Market Adoption
- The pace at which oncologists and healthcare systems integrate CyPath Lung into standard surveillance protocols.
Related topics